Supplement for FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis

Name: Supplement for FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis
Creator: Laura Ferris
Published: 2024-11-07T13:59:31.429Z
Keywords: Dermatology

Ferris, Laura; Bagel, Jerry; Huang, Yu-Huei; Pink, Andrew; Tyring, Stephen K; Kokolakis, Georgios; DeLozier, Amy M; Li, Shu; Shen, Yaung-Kaung; Iaconangelo, Charles; Ota, Takayuki; Bissonnette, Robert

doi:10.17632/23tcsdt2hc.1

Supplement for FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis

Published: 7 November 2024| Version 1 | DOI: 10.17632/23tcsdt2hc.1

Contributors:

,

Description

Supplemental material in support of the article "FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis"

Files

Funding

Janssen Research and Development

Supplement for FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis

Description

Files

Categories

Funding

Licence